drugset / Trial / NCT01760304

Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo

NCT01760304

Phase 4 Terminated 5 enrolled Brigham and Women's Hospital AstraZeneca · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

To investigate whether Budesonide/Formoterol (Symbicort ®) therapy can improve heart function at rest by decreasing lung hyperinflation in patients with COPD (Chronic Obstructive Pulmonary Disease).

Timeline

Start
2012-01
Primary completion
2012-07
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug Inhaled
Subject Formoterol Other / unclassified 4.5 ug Inhaled